Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
Daiichi Sankyo
Colorcon
Healthtrust
Accenture
Baxter
QuintilesIMS
Argus Health

Generated: December 14, 2018

DrugPatentWatch Database Preview

PATANASE Drug Profile

« Back to Dashboard

Which patents cover Patanase, and when can generic versions of Patanase launch?

Patanase is a drug marketed by Novartis Pharms Corp and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has thirty patent family members in twenty countries.

The generic ingredient in PATANASE is olopatadine hydrochloride. There are seventeen drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the olopatadine hydrochloride profile page.

Drug patent expirations by year for PATANASE
Pharmacology for PATANASE
Synonyms for PATANASE
(11Z)-11-[3-(Dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid hydrochloride
(Z)-11-[3-(Dimethylamino)propylidene]-6,11-dihydro-dibenz[b,e]oxepin-2-acetic acid hydrochloride
(Z)-11-[3-(Dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid hydrochloride ;Olopatadine HCL
(Z)-2-(11-(3-(dimethylamino)propylidene)-6,11-dihydrodibenzo[b,e]oxepin-2-yl)acetic acid hydrochloride
[(2Z)-2-[3-(dimethylamino)propylidene]-9-oxatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaen-5-yl]acetic acid hydrochloride
11-((Z)-3-(Dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid hydrochloride
11-((Z)-3-(Dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid, hydrochloride
113806-05-6 (Parent)
140462-76-6
2-[(11Z)-11-[3-(dimethylamino)propylidene]-6H-benzo[c][1]benzoxepin-2-yl]acetic acid hydrochloride
2-[(11Z)-11-[3-(dimethylamino)propylidene]-6H-benzo[c][1]benzoxepin-2-yl]acetic acid;hydrochloride
2XG66W44KF
AB0107085
AB2000599
AC1NR00D
AK163558
AKOS015895232
AKOS025149118
AL-4943A
Allelock
Allelock (TN)
ALO 4943A
ALO4943A
BCP9001022
Bio-0072
C-21208
CAS-140462-76-6
CCG-101141
CHEBI:31933
CHEMBL1719
CPD000469220
CS-2532
D01192
DE 114
Dibenz(b,e)oxepin-2-acetic acid, 11-(3-(dimethylamino)propylidene)-6,11-dihydro-, hydrochloride, (Z)-
Dibenz(b,e)oxepin-2-acetic acid, 11-(3-dimethylamino)propylidene)-6,11-dihydro-, hydrochloride, (Z)-
Dibenz[b,e]oxepin-2-acetic acid, 11-[3-(dimethylamino)propylidene]-6,11-dihydro-, hydrochloride (1:1), (11Z)-
DSSTox_CID_26486
DSSTox_GSID_46486
DSSTox_RID_81657
DTXSID0046486
EX-A1347
H06O056
HCl of KW 4679
HVRLZEKDTUEKQH-NOILCQHBSA-N
HY-B0426A
KS-1228
KW 4679
KW-4679
KW4679
LS-61598
MFCD00875716
MLS001401465
MolPort-003-986-408
NC00391
NCGC00164623-01
NCGC00263532-01
O-PPDS
O0361
Olopatadine (hydrochloride)
OLOPATADINE HCl
Olopatadine Hydrochlorde
OLOPATADINE HYDROCHLORIDE
Olopatadine hydrochloride (JP17/USAN)
Olopatadine hydrochloride (Opatanol)
Olopatadine hydrochloride [USAN:USP]
Olopatadine hydrochloride tablets (JP17)
Olopatadine hydrochloride, >=98% (HPLC)
Olopatadine hydrochloride, United States Pharmacopeia (USP) Reference Standard
Olopax
Olopine
Opatanol
Opatanol (TN)
Opatanol;Pataday;Patanase;Allelock
Pataday
Patadine
Patanol (TN)
Pazeo
PubChem18816
Q-201511
s2494
SAM001246802
SCHEMBL23213
SMR000469220
TL8000904
Tox21_112242
Tox21_112242_1
UNII-2XG66W44KF

US Patents and Regulatory Information for PATANASE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms Corp PATANASE olopatadine hydrochloride SPRAY, METERED;NASAL 021861-001 Apr 15, 2008 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Novartis Pharms Corp PATANASE olopatadine hydrochloride SPRAY, METERED;NASAL 021861-001 Apr 15, 2008 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for PATANASE
Drugname Dosage Strength RLD Date
➤ Subscribe Nasal Spray 0.665 mg/ Spray ➤ Subscribe ➤ Sign Up

Supplementary Protection Certificates for PATANASE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0040 France ➤ Sign Up PRODUCT NAME: OLOPATADINE HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/02/217/001 20020517
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Healthtrust
Merck
UBS
McKesson
Cerilliant
Argus Health
Chinese Patent Office
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.